A highly compact epitopebased markersuicide gene for easier and safer
RQR8 A universal safety switch for cellular therapies
Our final construct RQR8 is a 136aminoacid protein that is recognized by the antiCD34 antibody QBEnd10 the antibody used in the Miltenyi CliniMACS CD34 selection system It renders T cells highly susceptible to lysis by the therapeutic monoclonal rituximab We anticipate RQR8 will make Tcell therapy cheaper easier and safer
Targeted multiepitope switching enables straightforward positive
The EGFRbased safety switch has advantages over previously described cell surface markers that offer dual use as transduction markers and safety switches Studies utilizing RQR8 which incorporates a CD34 epitope and two CD20 mimotypes demonstrated complete depletion of T cells expressing monocistronic RQR8 following a multidose regimen of
RQR8 in particular is an immunological safety switch composed of QBEnd10 a CD34 epitope that can be used for positive selection during manufacturing two CD20 mimotopes that can be targeted with
Functional Validation of the RQR8 Suicide Marker Gene in Springer
RQR8 A universal safety switch for cellular therapies ResearchGate
Rqr8 Safety Switch
Targeted multiepitope switching enables straightforward positive
A compact markersuicide gene that enables clinical grade sorting and effective deletion using CD34 cliniMACS and rituximab respectively is generated and it is predicted that RQR8 will make Tcell gene therapy both safer and cheaper Cancer immunotherapy represents a rapidly developing field with potential to address shortcomings from current therapies A compact markersuicide gene reliant
Combinatorial suicide gene strategies for the safety of cell therapies
Download Citation RQR8 A universal safety switch for cellular therapies Cancer immunotherapy represents a rapidly developing field with potential to address shortcomings from current therapies
Keywords inducible caspase 8 inducible caspase 9 suicide gene safety switch RQR8 Introduction Given the recent surge of novel cellular therapies there is an urgent need to develop strategies to mitigate untoward events of genemodified cells Chimeric antigen receptor CAR redirected Tcells genemodified hematopoietic stem cells
Functional Validation of the RQR8 Suicide Marker Gene in CD19 CART
Rqr8 Safety Switch
Safety switch optimization enhances antibodymediated elimination of
Further we demonstrate functional coexpression of RQR8 alongside chimeric antigen receptors and transgenic Tcell receptors Finally we validate functional efficacy of RQR8 deletion in vivo through a murine haploidentical transfer model We predict that RQR8 will make Tcell gene therapy both safer and cheaper
RQR8 in particular is an immunological safety switch composed of QBEnd10 a CD34 epitope that can be used for positive selection during manufacturing two CD20 mimotopes that can be targeted with the FDAapproved CD20 antibody rituximab 2225 and a CD8 stalk for membrane anchoring Fig 1a
RQR8 A universal safety switch for cellular therapies
We believe that RQR8 as a safety switch will make CART cell therapy safer and less costly Similar content being viewed by others Nonviral specifically targeted CART cells achieve high safety and efficacy in BNHL Article Open access 31 August 2022 Generation of Suicide GeneModified Chimeric Antigen ReceptorRedirected TCells for Cancer
In our study we incorporated the suicide gene RQR8 into CART cells so it enabled rituximab to eliminate vectortransgeneexpressing T cells via antibodydependent cellmediated cytotoxicity and complement dependent cytotoxicity We believe that RQR8 as a safety switch will make CART cell therapy safer and less costly Keywords Antibody